metaEvidence - overview

meta|evidence oncology

Living systematic review and meta-analysis

breast cancer - HER2-positive
es-BC - HER2 negative - (neo)adjuvant (NA) 1
es-BC - HER2 positive - (neo)adjuvant (NA) 4
la/mBC - HER2 positive
la/mBC - HER2 positive - (neo)adjuvant (NA)
la/mBC - HER2 positive - 1st Line (L1) 5
la/mBC - HER2 positive - 2nd Line (L2) 13

antibody–drug conjugate
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
HER inhibitor
HER2 inhibitor
trastuzumab based treatment
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel

versus all
vs HER inhibitor
vs HER2 inhibitor
vs trastuzumab based treatment
vs trastuzumab
vs trastuzumab plus endocrine therapy
vs TKI anti HER1/EGFR and HER2/neu
vs lapatinib based treatment
vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

button bars forest bayes pooled summary circles


			deaths (OS)
es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open